Short-Term Efficacy and Safety of Leflunomide in the Treatment of Active Rheumatoid Arthritis in Everyday Clinical Use: Open-Label, Prospective Study

Clinical Drug Investigation

Volumn 24, Issue 2, 2004, Pages 103-112

  Nguyen, Minh ^a,c   Kabir, Marmar ^b   Ravaud, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SANOFI   (France)

^c université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE;

ACUTE DISEASE; ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FRANCE; HEADACHE; HUMAN; HYPERTENSION; JOINT; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MOBILIZATION; MULTICENTER STUDY; NAUSEA; NEURALGIA; OFFICE WORKER; OPEN STUDY; PHARYNGITIS; PHASE 4 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; SIDE EFFECT; SJOEGREN SYNDROME; SKIN APPENDAGE DISEASE; SKIN DISEASE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 1542343849     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424020-00005     Document Type: Article

References (23)

1. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol 2001; 28 (6): 1431-52
2. Choy EH, Scott DL. Drug treatment of rheumatic diseases in the 1990s: achievements and future developments. Drugs 1997; 53 (3): 337-48
3. Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2001; 2 (1): 125-37
4. Smolen JS, Graninger WB, Emery P. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford) 2000; 39 (7): 689-92
5. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58 (6): 1137-64
6. Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61 (4): 635-42
7. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38 (11): 1595-603
8. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42 (7): 1322-8
9. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate: Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159 (21): 2542-50
10. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 (9149): 259-66
11. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913-23
12. Felson D, Anderson J, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
13. Harrison BJ, Symmons DP, Barrett EM, et al. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis: American Rheumatism Association. J Rheumatol 1998; 25 (12): 2324-30
14. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (1): 44-8
15. Guillemin F, Braincon S, Pourel J. Measurement of the functional capacity in rheumatoid polyarthritis: a French adaptation of the Health Assessment Questionnaire (HAQ) [in French]. Rev Rheum Mal Osteoartic 1991; 58 (6): 459-65
16. Vrijhoef H, Diederiks J, Spreeuwenberg C, et al. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62 (5): 419-22
17. Dougados M, Larrey D, Solal-Celigny P, et al. Safety of leflunomide in patients with rheumatoid arthritis: results from the RELIEF study [abstract]. Annual European Congress of Rheumatology (EULAR) 2002; Stockholm Jun 12-15 2002
18. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (6): 655-65
19. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342 (25): 1878-86
20. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342 (25): 1887-92
21. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998; 25 (3): 408-16
22. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19 (12): 1885-94
23. Mroczkowski PJ, Weinblatt ME, Kremer JM. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol 1999; 17 (6 Suppl. 18): S66-8